1.1 Comprehensive Ophthalmic & Medical History for Retina Patients

Comprehensive Ophthalmic & Medical History for Retina Patients

History intake in a vitreoretinal subspecialty practice demands precision, depth, and structured inquiry. The neurosensory retina, retinal pigment epithelium (RPE), and choroidal vasculature serve as direct end-organ targets for numerous chronic systemic pathologies. Certified Retina Technicians collect and document accurate history under supervision so the licensed clinician can interpret risk, establish a diagnosis, and choose treatment.

---

Chief Complaint & History of Present Illness (HPI)

A focused retinal history expands beyond generic visual blur. Technicians should apply a structured framework—such as the OPQRST-A approach (Onset, Provocation/Palliation, Quality, Region/Laterality, Severity, Timing, Associated symptoms)—tailored specifically to vitreoretinal pathology:

• Onset & Chronology: Did visual changes develop abruptly over seconds or minutes (suggesting vascular occlusion, vitreous hemorrhage, or ischemic optic neuropathy) or insidiously over months or years (characteristic of non-exudative age-related macular degeneration or chronic diabetic macular edema)?
• Quality of Visual Disturbance: Distinguish between blur, dark shadows or curtains (field defects), image distortion or wavy lines (metamorphopsia), micropsia (objects appearing smaller), macropsia (objects appearing larger), or central blind spots (scotomas). Metamorphopsia typically reflects foveal structural disruption, such as subretinal fluid or epiretinal traction, whereas a fixed dark curtain strongly suggests neurosensory retinal detachment.
• Laterality & Field Distribution: Establish whether symptoms are strictly monocular or binocular. Pinpoint the visual field quadrant involved (e.g., a superior visual field curtain corresponds to an inferior retinal detachment due to the optical inversion of the ocular lens).
• Associated Positive & Negative Symptoms:
  • Photopsia (flashes of light): Characteristic of mechanical vitreoretinal traction on the neurosensory retina. Document frequency, duration, lighting conditions, and whether flashes occur temporally.
  • Entopsias / Floaters: Distinguish solitary, long-standing, translucent floaters from an acute shower of dark, black dots or cobwebs (often representing liberated red blood cells from a torn vessel or pigment granules from a full-thickness retinal break).
  • Pain vs. Painlessness: The vast majority of retinal diseases are completely painless. The presence of significant ocular or periocular pain immediately broadens the differential diagnosis to include anterior or intermediate uveitis, scleritis, endophthalmitis, neovascular glaucoma, or optic neuritis.

---

Past Ocular History (POHx): The Vitreoretinal Record

Past ocular interventions permanently modify intraocular dynamics, vitreous architecture, and surgical anatomy. Technicians must methodically query and document:

Prior Vitreoretinal Surgeries

• Pars Plana Vitrectomy (PPV): Record the surgical indication, approximate date, operating surgeon, and whether an intraocular endotamponade was placed (air, short-acting sulfur hexafluoride [SF6], long-acting perfluoropropane [C3F8], or silicone oil). Patients with active intraocular gas bubbles cannot travel by air, ascend to high altitudes, or receive nitrous oxide anesthesia.
• Scleral Buckling: Inquire about encircling bands or localized radial/segmental silicone sponges. Scleral buckles induce an axial elongation resulting in an induced myopic shift of 1.00 to 3.00 diopters, can restrict ocular motility, and may rarely erode or become infected years later.
• Pneumatic Retinopexy: Document prior outpatient gas injection coupled with cryotherapy or laser retinopexy.

Prior Retinal Laser Photocoagulation

• Panretinal Photocoagulation (PRP): High-intensity, scatter laser applied to peripheral ischemic retina in proliferative diabetic retinopathy or ischemic retinal vein occlusion. Patients typically exhibit constricted visual fields, diminished night vision (nyctalopia), and altered contrast sensitivity.
• Focal or Grid Macular Laser: Historical thermal laser applied to microaneurysms or diffuse macular edema; identifiable on fundus examination as localized atrophic chorioretinal scars.
• Demarcation / Barrier Laser: Chorioretinal laser scars placed around retinal tears or localized asymptomatic detachments to prevent progressive subretinal fluid accumulation.

Intravitreal Pharmacotherapy History

Intravitreal injections represent the most common procedure performed in retina clinics. Technicians must document:

• Specific therapeutic agent: anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab, ranibizumab, aflibercept, faricimab, or brolucizumab; or intraocular corticosteroids including triamcinolone acetonide, dexamethasone intravitreal implant, or fluocinolone acetonide implant.
• Cumulative injection count and treatment frequency (e.g., monthly, treat-and-extend intervals).
• Date and eye (laterality) of the most recent injection.
• Prior post-injection adverse reactions, such as intraocular pressure (IOP) spikes, sterile intraocular inflammation, or infectious endophthalmitis.

Anterior Segment & Glaucoma History

• Cataract Surgery: Document lens status (phakic, pseudophakic, or aphakic). For pseudophakic patients, note whether the posterior capsule is intact or whether an Nd:YAG laser capsulotomy was performed. Capsulotomy increases the lifetime incidence of rhegmatogenous retinal detachment.
• Glaucoma Drops: Document active topical regimens. Topical prostaglandin analogues (e.g., latanoprost, travoprost, bimatoprost) can induce or aggravate pseudophakic cystoid macular edema (Irvine-Gass syndrome) and anterior uveitis.

---

Past Medical History (PMHx) & Retinal Pathophysiology

Vitreoretinal microvasculature provides an unobstructed window into systemic vascular and metabolic health. Technicians must capture detailed metrics for the following chronic conditions:

1. Diabetes Mellitus (DM)

• Type & Chronological Duration: Differentiate Type 1 from Type 2 diabetes. Longer diabetes duration is an important non-modifiable retinopathy risk factor, but an individual's findings also depend on glycemic exposure, blood pressure, renal disease, pregnancy, and other clinical factors.
• Glycemic Control (HbA1c): Glycosylated hemoglobin reflects average blood glucose levels over the prior 8 to 12 weeks. HbA1c estimates recent average glycemia. Record the value and trend when available and reinforce the individualized goal established by the patient's medical team rather than labeling one threshold appropriate for everyone.
• Renal Function & Diabetic Nephropathy: Renal status correlates directly with retinopathy severity. Document microalbuminuria, serum creatinine, and hemodialysis dependence. In end-stage renal disease (ESRD), systemic fluid overload exacerbates recalcitrant macular edema.

2. Systemic Hypertension & Cardiovascular Disease

• Hypertension: Elevated systemic blood pressure accelerates retinal arteriolar sclerosis, cotton-wool spot formation, and flame-shaped retinal hemorrhages. Extreme elevations (>180/120 mmHg) can precipitate malignant hypertensive retinopathy with bilateral optic disc edema, macular star exudates, and Elschnig spots.
• Cardiovascular & Cerebrovascular Disease: Inquire about coronary artery disease, myocardial infarction, transient ischemic attacks (TIAs), and strokes. Carotid artery stenosis can manifest as Ocular Ischemic Syndrome (OIS), featuring mid-peripheral blot hemorrhages, dilated irregular veins, and anterior segment neovascularization.
• Atrial Fibrillation & Valvular Disease: These conditions generate systemic emboli that travel through the ophthalmic artery, lodging in the central retinal artery or branch arterioles (manifesting as calcific, platelet-fibrin, or cholesterol Hollenhorst plaques).

3. Hematologic & Autoimmune Disorders

• Sickle Cell Hemoglobinopathy: Sickle cell disease (HbSS) and especially sickle cell hemoglobin C (HbSC) cause peripheral arteriolar occlusion leading to sea-fan neovascularization, vitreous hemorrhage, and tractional retinal detachment.
• Connective Tissue & Vasculitic Diseases: Systemic lupus erythematosus, granulomatosis with polyangiitis, and sarcoidosis produce retinal vasculitis, periphlebitis (candle-wax drippings), and severe microvascular occlusion.

---

Clinical Table: Systemic Conditions and Retinal Implications

---

Medication History: Anticoagulants, Antiplatelets & Retinal Toxicity

Anticoagulants & Antiplatelets

Technicians must document the exact drug name, daily dose, indication, and recent laboratory monitoring parameters (e.g., International Normalized Ratio [INR] for warfarin):

• Vitamin K Antagonists: Warfarin (Coumadin).
• Direct Oral Anticoagulants (DOACs): Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa).
• Antiplatelet Agents: Aspirin, clopidogrel (Plavix), ticagrelor (Brilinta).

Clinical Significance: Record anticoagulant or antiplatelet name, dose, indication, last use, and any bleeding history. The treating and prescribing clinicians decide whether therapy continues or changes for a procedure; the technician must not advise interruption independently.

Retinal Toxicity Screening Baselines

Several systemic medications exert direct, irreversible toxicity on the neurosensory retina and retinal pigment epithelium:

• Hydroxychloroquine (Plaquenil) & Chloroquine: Used for rheumatoid arthritis and lupus. The American Academy of Ophthalmology (AAO) screening guidelines emphasize that the primary risk factor is a daily dose exceeding 5.0 mg/kg of actual body weight (not ideal weight). Risk rises with duration and is also affected by daily dose relative to real weight, renal disease, tamoxifen use, and age at treatment initiation; current screening guidance should control rather than an older cumulative-dose rule. The 2025 AAO revision recommends baseline fundus examination, OCT, and wide-pattern fundus autofluorescence near treatment initiation. OCT and wide-pattern FAF are the primary annual screening tests; visual fields or multifocal ERG can confirm uncertain findings, and the plan should assess both parafoveal and pericentral patterns rather than rely on race alone.
• Pentosan Polysulfate Sodium (Elmiron): Prescribed for interstitial cystitis. Chronic use produces a unique toxic maculopathy characterized by hyperpigmented macular spots, RPE atrophy, and profound nyctalopia mimicking pattern dystrophy.
• Phenothiazines (Thioridazine, Chlorpromazine): High doses cause widespread, severe chorioretinal atrophy and pigmentary degeneration.
• Tamoxifen: Selective estrogen receptor modulator used in breast cancer treatment; can cause refractile crystalline maculopathy, punctate intraretinal deposits, and macular edema.

---

Family and Social History

Family History (FamHx)

Inquire systematically about first-degree relatives regarding:

• Age-Related Macular Degeneration (AMD): First-degree family history is an important AMD risk factor associated with multiple genetic and environmental influences; record the affected relative and age or disease details when known.
• Inherited Retinal Dystrophies: Retinitis pigmentosa (RP), Stargardt disease, Best vitelliform macular dystrophy, and Usher syndrome. Establish exact inheritance patterns (autosomal dominant, autosomal recessive, X-linked, or mitochondrial).
• Rhegmatogenous Retinal Detachment (RRD): Inquire about familial high myopia, Stickler syndrome, or lattice degeneration.

Social History (SocHx)

• Tobacco Smoking: Quantify in pack-years (packs per day multiplied by years smoked), distinguishing current smokers, former smokers, and never-smokers. Smoking is an important modifiable AMD risk factor. Record current or former use and pack-years without promising an exact individual risk multiplier.
• Occupational & Functional Demands: Document driving status (day vs. night), occupational near-vision demands (computer displays, micro-assembly), and recreational visual needs to tailor low-vision aids and treatment plans.